Trade Gilead ^GILD

What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?

Gilead Sciences' (GILD) Overweight Rating Reaffirmed at Cantor Fitzgerald - Stock Observer

Gilead Sciences (NASDAQ:GILD) Given Overweight Rating at Cantor Fitzgerald - Stock Observer

Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - Stock Observer

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Daily Political

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co.

GILD Maintained by Morgan Stanley -- Price Target Lowered to $16

Morgan Stanley Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $163.00

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - Stock Observer

Nurix Extends Gilead Oncology Research Collaboration For Two Years

Zacks Research Lowers Earnings Estimates for Gilead Sciences

Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan - Zolmax

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional

Biotech Stocks To Watch Now - October 2nd - Daily Political

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Biotech Stocks To Watch Now - October 2nd - Zolmax

Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 Shares - Daily Political

Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD

HIV prevention drug hailed as breakthrough, but who gets access?

Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research

Zacks Research Downgrades Gilead Sciences (NASDAQ:GILD) to Hold - Stock Observer

GILD: HIV Growth Still Leads, Oncology And Immunology Now Carry More Weight

Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire

Best Medical Stocks To Watch Today - September 29th - Markets Daily

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?

A human single-cell atlas identifies OLR1 + scar-associated macrophages as a potential therapeutic target for chronic liver disease

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?

Gilead's HIV Concentration or Pfizer's Patent Cliff: Which Risk is Easier to Own?

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Reviewing Gilead Sciences (NASDAQ:GILD) & Protalix BioTherapeutics (NYSE:PLX) - Stock Observer

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.

FY2026 EPS Estimate for Gilead Sciences Boosted by Analyst - Daily Political

Biotech Stocks To Follow Now - September 23rd - Stock Observer

Medical Stocks To Watch Today - September 22nd - Stock Observer

FY2027 EPS Forecast for Gilead Sciences Boosted by Analyst - Daily Political

Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know

State Street Corp Raises Position in Gilead Sciences, Inc. $GILD

Gilead Sciences FY2026 EPS Increased by Erste Group Bank

Biotech Stocks To Consider - September 19th - Zolmax

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Drugmakers move closer to launch landmark HIV drug as CDSCO eases approval process

Biotech Stocks To Watch Now - September 21st - Daily Political

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

GILD: HIV Prevention Promise Faces A Harder Test, Growth Still Looks Thin

Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Why Morgan Stanley likes Gilead's HIV prevention play

Gilead Sciences (NASDAQ:GILD) Rating Increased to Buy at Wall Street Zen

Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen

Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $435,870.00 in Stock - Daily Political

Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Top Medical Stocks To Watch Today - September 18th - Daily Political

Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD

Top Medical Stocks To Keep An Eye On - September 17th - Stock Observer

Dr Reddy's inks licensing deal with Gilead for once-yearly HIV lenacapavir

Biotech Stocks To Keep An Eye On - September 17th - Stock Observer

Dr Reddy's Labs Secures License for Gilead's Revolutionary Once-Yearly HIV Prevention Drug, ETPharma

Dr. Reddy's expands Gilead pact for HIV prevention drug

Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $432,660.00 in Stock

Johanna Mercier Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - Stock Observer

Gilead Partners with PAHO to Expand Access to HIV Prevention Drug in Latin America and Caribbean, ETPharma

Medical Stocks To Consider - September 15th - Zolmax

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Stock Observer

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - Daily Political

Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on September 15th

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD

Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD

Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales

16,506 Shares in Gilead Sciences, Inc. $GILD Bought by Bullseye Investment Management LLC - Stock Observer

Best Medical Stocks To Research - September 11th - Daily Political

Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth

Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service